TherapeuticsMD, Inc. cash flow to debt ratio of 39.76% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

TherapeuticsMD, Inc.'s free cash flow has increased 231.15% from $732.00K last year to $2.42M, signaling increasing performance

TherapeuticsMD, Inc.'s debt to equity ratio is 0.22, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

TherapeuticsMD, Inc.'s debt has decreased relative to shareholder equity from 0.26 last year to 0.22 today, signaling strengthened financials

TherapeuticsMD, Inc. has negative EBITDA, making leverage ratio unreliable

TherapeuticsMD, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

TherapeuticsMD, Inc.'s profit margin has increased (-104.31%) in the last year from -123.85% to 5.34%, signaling increasing performance

TherapeuticsMD, Inc.'s short-term assets of $14.45M exceed its short-term liabilities of $4.79M

TherapeuticsMD, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

TherapeuticsMD, Inc.'s return on equity of 0.66%, is lower than 15.00%, indicating bad performance

TherapeuticsMD, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

TherapeuticsMD, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

TherapeuticsMD, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

TherapeuticsMD, Inc. has a free cash flow yield of 10.63%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

TherapeuticsMD, Inc.'s yearly earnings has increased -73.91% since last year from $-2.18M to $-569.00K, signaling increasing performance

TherapeuticsMD, Inc.'s yearly revenue has increased 71.61% since last year from $1.76M to $3.02M, signaling increasing performance

ROIC -8.10% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

TherapeuticsMD, Inc.'s 3-year revenue CAGR of -64.91% is negative, indicating declining revenue over the past 3 years

TherapeuticsMD, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

TherapeuticsMD, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

TherapeuticsMD, Inc. has insufficient data to evaluate this check.

TherapeuticsMD, Inc. has an earnings yield of 0.79%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

TherapeuticsMD, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

TherapeuticsMD, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

TherapeuticsMD, Inc. is overvalued relative to its fair value price of -4.74 based on Earnings Fair Value model

TherapeuticsMD, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.

TherapeuticsMD, Inc. has a price-to-book ratio of 0.85x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

TherapeuticsMD, Inc. has a price-to-sales ratio of 6.80x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue